"Market Access Impact: Psoriasis (EU5)" is now available at Fast Market Research

Price and reimbursement are stopping physicians from prescribing the drugs they want.

In the psoriasis market, brands are gaining or losing market share due to, in many cases, avoidable barriers. There's a clear and huge separation in number of prescriptions between the three market leaders and the remainder of the market.

If barriers did not exist, the playing field would be significantly more level among the drugs with lower market share, and the current strongest player would lose the lead.

The report compares 8 major psoriasis treatments - Humira, Stelara, Enbrel, Remicade, Cosentyx, Inflectra, Remsima, and Otezla. You'll get a detailed picture of what prevents doctors from prescribing your brand, who you're losing market share to, and who you're taking it from.

That's information you can use to win back lost share and compete more effectively.

Full Report Details at
- http://www.fastmr.com/prod/1180393_market_access_impact.aspx?afid=301

Not your market? Click here to see the US report

Reasons to Get this Report

Get Answers to Key Questions about Psoriasis Drug Brands

* Cosentyx (secukinumab; Novartis) - Which one barrier is most significantly effecting the prescription of this drug? Could it be overcome?
* Humira (adalimumab; AbbVie) - Humira is significantly gaining against the other brands, but which factor is it that makes this the drug of choice?
* Enbrel (etanercept; Pfizer) - Is Enbrel's price point benefiting its uptake or inhibiting it?
* Inflectra (Infliximab, Pfizer) - Which medications are being chosen as substitutes to Inflectra and what is the primary factor causing this?
* Otezla (apremilast; Celgene) - How does Otezla fall within the guidelines and what does this do to prescribing rates as compared to its competitors?
* Remicade (infliximab; MSD) - Remicade has multiple preferential factors, however why is it still losing out to the market leader?
* Remsima (infliximab; Mundipharma/Napp) - What factor is holding Remsima back from winning market share?
* Stelara (ustekinumab; Janssen Biotech) - Which one barrier is causing the biggest loss for Stelara and could it be overcome?

Top Takeaways

* Of physicians affected by barriers, many cannot prescribe the drugs they actually want: See how inability to reimburse, price, and availability on the formulary are the key inhibitors.
* Fierce competition among top three drugs: the top three drugs are all making gains due to market barriers, but one is starting to outmatch the competition.
* The bottom of the market are losing out most to barriers: Although a close race, a change to the condition of the barriers, or coping strategy could see one drug leave the others behind.
* Losing drugs hold minimal prescription usage: The percentage of the three least prescribed drugs added together is still less than 50% than that of the leading drugs.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Market Access Impact: Psoriasis (US)
- Market Access Impact: HIV (EU5)
- Market Access Impact: Renal Cell Carcinoma (EU5)
- NPS+ Psoriasis (EU5)
- Market Access Impact: HIV (US)